Read by QxMD icon Read

Pigment Cell & Melanoma Research

Erica Riveiro-Falkenbach, Yolanda Ruano, Rosa M García-Martín, David Lora, Metehan Cifdaloz, Francesco Acquadro, Claudio Ballestin, Pablo L Ortiz-Romero, María S Soengas, José L Rodríguez-Peralto
DEK is an oncoprotein involved in a variety of cellular functions, such as DNA repair, replication and transcriptional control. DEK is preferentially expressed in actively proliferating and malignant cells, including melanoma cell lines in which DEK was previously demonstrated to play a critical role in proliferation and chemoresistance. Still, the impact of this protein in melanoma progression remains unclear. Thus, we performed a comprehensive analysis of DEK expression in different melanocytic tumors. The immunostaining results of 303 tumors demonstrated negligible DEK expression in benign lesions...
November 28, 2016: Pigment Cell & Melanoma Research
F Boukari, P M Dugourd, M Chassang, L Mondot, T Passeron, J P Lacour, H Montaudie
The combination of BRAF and MEK inhibitors has improved the prognosis of patients with BRAFV600-mutated metastatic melanoma (Larkin et al., 2014). The toxicity profiles of these drugs are mostly defined by gastrointestinal events, photosensitivity, hepatitis, and arthralgia (Larkin et al., 2014). We report a case of posterior reversible encephalopathy syndrome (PRES) induced by vemurafenib and cobimetinib. A 68-year-old man, with neither a medical history nor any treatment, was surgically treated in November 2015 for stage IIB chest melanoma (superficial-spreading melanoma, Breslow 7 mm, with a high mitotic rate and without ulceration)...
November 25, 2016: Pigment Cell & Melanoma Research
Jacqueline Turner, Kasey Couts, Jamie Sheren, Siriwimon Saichaemchan, Witthawat Ariyawutyakorn, Izabela Avolio, Ethan Cabral, Magdelena Glogowska, Carol Amato, Steven Robinson, Jennifer Hintzsche, Allison Applegate, Eric Seelenfreund, Rita Gonzalez, Keith Wells, Stacey Bagby, John Tentler, Aik-Choon Tan, Joshua Wisell, Marileila Varella-Garcia, William Robinson
Genomic rearrangements resulting in activating kinase fusions have been increasingly described in a number of cancers including malignant melanoma, but their frequency in specific melanoma subtypes has not been reported. We used break-apart fluorescence in-situ hybridization (FISH) to identify genomic rearrangements in tissues from 59 patients with various types of malignant melanoma including acral lentiginous, mucosal, superficial spreading, and nodular. We identified four genomic rearrangements involving the genes BRAF, RET, and ROS1...
November 19, 2016: Pigment Cell & Melanoma Research
Emily Yiping Gan, Viktoria Eleftheriadou, Samia Esmat, Iltefat Hamzavi, Thierry Passeron, Markus Böhm, Tag Anbar, Boon Kee Goh, Cheng-Che Eric Lan, Harvey Lui, M Ramam, Noufal Raboobee, Ichiro Katayama, Tamio Suzuki, Davinder Parsad, Vaneeta Seth, Henry W Lim, Nanja van Geel, Sanjeev Mulekar, John Harris, Richard Wittal, Laila Benzekri, Yvon Gauthier, Prasad Kumarasinghe, Steven Tien Guan Thng, Caio Cesar Silva de Castro, Marwa Abdallah, Charlotte Vrijman, Marcel Bekkenk, Julien Seneschal, Amit G Pandya, Khaled Ezzedine, Mauro Picardo, Alain Taïeb
The Vitiligo Global Issues Consensus Conference (VGICC), through an international e-Delphi consensus, concluded that "repigmentation" and "maintenance of gained repigmentation" are essential core outcome measures in future vitiligo trials. This VGICC position paper addresses these core topics in two sections and includes an atlas depicting vitiligo repigmentation patterns and color match. The first section delineates mechanisms and characteristics of vitiligo repigmentation and the second summarizes the outcomes of international meeting discussions and two e-surveys on vitiligo repigmentation, which had been carried out over three years...
November 19, 2016: Pigment Cell & Melanoma Research
Amal Maouia, Laura Sormani, Monia Youssef, Ahmed Noureddine Helal, Asma Kassab, Thierry Passeron
Vitiligo and Alopecia areata (AA) are autoimmune T cell-mediated diseases of the skin that share the implication of the IFNγ pathway in their pathophysiology. C-X-C motif chemokine receptor 3 (CXCR3) and its ligands, C-X-C motif chemokine ligand 9 (CXCL9), CXCL10 and CXCL11, are linked to the Th1 pattern and have been suggested as one of the most relevant chemokine axes that promote T cell migration in different autoimmune and inflammatory processes (Lacotte et al., 2009). Chemokines play an important role in regulating the homing of immune cells (Vazirinejad et al...
November 12, 2016: Pigment Cell & Melanoma Research
(no author information available yet)
No abstract text is available yet for this article.
November 12, 2016: Pigment Cell & Melanoma Research
John J Park, Alan V Boddy, Xiaoman Liu, David Harris, Vincent Lee, Richard F Kefford, Matteo S Carlino
The combination of dabrafenib and trametinib is a standard of care for the management of BRAF mutant metastatic melanoma. Clinical trials excluded patients with end-stage kidney disease (ESKD) and as such no data are available regarding the safety, efficacy and pharmacokinetics of these drugs in such patients. Here, we present the case of a 78 year-old male patient with ESKD managed with haemodialysis (HD), treated with dabrafenib and trametinib at reduced doses. The patient has had a partial response, and this response continues at 9 months since our last follow up without any dose escalation...
November 10, 2016: Pigment Cell & Melanoma Research
Kristen S Hill, Minjung Kim
Cancer cells constantly reprogram their metabolism to meet anabolic and catabolic demands in real time. Increased aerobic glycolysis (the Warburg effect) is associated with highly proliferative tumors, since it confers several advantages to proliferating tumor cells by providing rapid ATP production from glycolysis and macromolecules (building blocks) for cell division. On the other hand, mitochondria-dependent oxidative phosphorylation (OxPhos) generates the maximal amount of ATP from glucose. Although underappreciated, OxPhos is also utilized to support growth of cancer cells, especially for "oxidative tumors" such as lymphomas, glioblastomas, and melanomas...
November 10, 2016: Pigment Cell & Melanoma Research
Vincent Laville, Sigrid Le Clerc, Khaled Ezzedine, Jean-François Zagury
No abstract text is available yet for this article.
November 2, 2016: Pigment Cell & Melanoma Research
Jarred J Bultema, Santiago M Di Pietro
The formation of the melanosome - the organelle responsible for synthesizing the melanin pigment found in hair, skin, and eyes - has long been studied as a model for the specialized development of organelles. In part this is due to the relative ease in identifying genes that impact pigmentation based on subtle to severe forms of albinism. The melanosome belongs to a family of lysosome-related organelles (LROs) that share some characteristics including an acidic lumen, part of their protein content, and biogenesis mechanisms...
November 2, 2016: Pigment Cell & Melanoma Research
Leonie C Jacobs, Tamar Nijsten
We have read with interest the study by Laville et al. that was published in the September 2016 issue of PCMR (Laville et al., 2016) and that represents the second genome-wide association study of facial solar lentigines. This study (SU.VI.MAX cohort) showed two novel genetic regions, both located on chromosome 6 [6p22 intergenic region (p=1.6×10(-6) ) and 6p21 USP81P / HLA-C region (p=2.5×10(-7) )] but both not significantly associated with solar lentigines based on the genome-wide association study. Laville et al...
November 1, 2016: Pigment Cell & Melanoma Research
Edward J Hartsough, Michael J Vido
No abstract text is available yet for this article.
November 1, 2016: Pigment Cell & Melanoma Research
Monika B Dolinska, Nicole Kus, Katie Farney, Paul T Wingfield, Brian P Brooks, Yuri V Sergeev
: Oculocutaneous albinism Type 1 (OCA1) is an autosomal recessive disorder caused by mutations in the tyrosinase gene. Two subtypes of OCA1 have been described: severe OCA1A with complete absence of tyrosinase activity and less severe OCA1B with residual tyrosinase activity. Here, we characterize the recombinant human tyrosinase intra-melanosomal domain and mutant variants, which mimic genetic changes in both subtypes of OCA1 patients. Proteins were prepared using site-directed mutagenesis, expressed in insect larvae, purified by chromatography, and characterized by enzymatic activities- tryptophan fluorescence, and Gibbs free energy changes...
October 24, 2016: Pigment Cell & Melanoma Research
Viviana Anelli, Marina Mione
Cancer-associated fibroblasts (CAFs) are an activated sub-population of stromal fibroblast that have the ability to synthesize, deposit and remodel the extracellular matrix. They produce and secrete cytokines and growth factors that promote tumor growth, angiogenesis, inflammation and contribute to drug resistance (Micke and Ostman, 2005). CAFs are abundant constituents of many epithelial tumors. Less is known about CAFs in non-epithelial cancers, such as melanoma, but in vitro data suggest similar roles in tumor development and progression (Kim et al...
October 23, 2016: Pigment Cell & Melanoma Research
Lluis Montoliu, Michael S Marks
No abstract text is available yet for this article.
October 19, 2016: Pigment Cell & Melanoma Research
Nikki R Adler, Andrew Haydon, Catriona A McLean, John W Kelly, Victoria J Mar
Metastasis represents the end product of an elaborate biological process, which is determined by a complex interplay between metastatic tumour cells, host factors and homoeostatic mechanisms. Cutaneous melanoma can metastasize haematogenously or lymphogenously. The three predominant models that endeavour to explain the patterns of melanoma progression are the stepwise spread model, the simultaneous spread model and the model of differential spread. The time course to the development of metastases differs between the different metastatic routes...
October 19, 2016: Pigment Cell & Melanoma Research
Shosuke Ito, Ludger Kolbe
No abstract text is available yet for this article.
October 5, 2016: Pigment Cell & Melanoma Research
Justine V Cohen, Hussain Tawbi, Kim A Margolin, Ravi Amravadi, Marcus Bosenberg, Priscilla K Brastianos, Veronica L Chiang, John de Groot, Isabella C Glitza, Meenhard Herlyn, Sheri L Holmen, Lucia B Jilaveanu, Andrew Lassman, Stergios Moschos, Michael A Postow, Reena Thomas, John A Tsiouris, Patrick Wen, Richard M White, Timothy Turnham, Michael A Davies, Harriet M Kluger
Melanoma central nervous system metastases are increasing, and the challenges presented by this patient population remain complex. In December 2015, the Melanoma Research Foundation and the Wistar Institute hosted the First Summit on Melanoma Central Nervous System (CNS) Metastases in Philadelphia, Pennsylvania. Here, we provide a review of the current status of the field of melanoma brain metastasis research; identify key challenges and opportunities for improving the outcomes in patients with melanoma brain metastases; and set a framework to optimize future research in this critical area...
September 12, 2016: Pigment Cell & Melanoma Research
(no author information available yet)
No abstract text is available yet for this article.
September 9, 2016: Pigment Cell & Melanoma Research
Eleonora Leucci, Elizabeth A Coe, Jean-Christophe Marine, Keith W Vance
Malignant melanoma is a highly aggressive form of skin cancer, the incidence of which is rising rapidly. Although MAPK-targeting therapies and immune checkpoint blockade are emerging as attractive therapeutic approaches, their utility is limited to only a subset of patients who often acquire resistance. A better understanding of the aetiologies and genetic underpinnings of melanoma is therefore critical for the development of adjuvant or alternative therapeutic strategies aimed at increasing the proportion of responders and improving treatment efficacy...
September 8, 2016: Pigment Cell & Melanoma Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"